drugset / Trial / NCT01313598

GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

NCT01313598 ↗

Phase 1 Completed 20 enrolled Lakefront Biotherapeutics NV
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety and tolerability of GLPG0187 administered through continuous intravenous infusion and to explore its preliminary clinical efficacy in patients with solid tumors.

Timeline

Start
2011-03
Primary completion
2013-05
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0187 Small molecule — Intravenous

Indications